行情

VRML

VRML

Vermillion
NASDAQ

实时行情|Nasdaq Last Sale

0.7300
-0.0400
-5.19%
已收盘, 16:00 11/19 EST
开盘
0.7900
昨收
0.7700
最高
0.8400
最低
0.7028
成交量
19.78万
成交额
--
52周最高
1.570
52周最低
0.2701
市值
7,098.41万
市盈率(TTM)
-4.0000
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

VRML 新闻

  • Vermillion, Inc. (VRML) CEO Valerie Palmieri on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.11/13 04:01
  • Vermillion reports Q3 results
  • seekingalpha.11/13 02:11
  • Vermillion Q3 EPS $(0.04), Same YoY, Sales $1.285M Beat $922K Estimate
  • Benzinga.11/12 21:20
  • Vermillion Reports Third Quarter 2019 Financial Results
  • GlobeNewswire.11/12 21:05

更多

所属板块

生物技术和医学研究
+2.16%
制药与医学研究
+0.78%

热门股票

名称
价格
涨跌幅

VRML 简况

Vermillion, Inc. is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician's clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery. It developed OVA1 through pre-clinical studies in collaboration with various academic medical centers encompassing over 2,500 clinical samples. OVA1 is validated in a multi-center clinical trial encompassing approximately 30 sites reflective of the diverse nature of the clinical centers, at which ovarian adnexal masses are evaluated. Its ASPiRA LABS is a laboratory that provides diagnostic services using a biomarker-based diagnostic algorithm to inform clinical decision making and personalized treatment plans.
展开

Webull提供Vermillion, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。